After wrestling once again with what passes muster as abuse deterrence, two FDA advisory committees voted 9-6 Wednesday to recommend approval of Pfizer Inc.'s Troxyca ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment when alternative options are inadequate.